Milosz Wilczynski1, Justyna Danielska2, Daria Domanska-Senderowska3, Monika Dzieniecka4, Bozena Szymanska5, Andrzej Malinowski6. 1. Endoscopy and Gynecologic Oncology, Department of Operative Gynecology, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland. 2. Radiotherapy Department, Medical University in Lodz, Lodz, Poland. 3. Department of Biomedicine and Genetics, Medical University of Lodz, Lodz, Poland. 4. Department of Pathology, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland. 5. Central Laboratory, Medical University in Lodz, Lodz, Poland. 6. Department of Surgical and Endoscopic Gynecology, Medical University in Lodz, Lodz, Poland.
Abstract
INTRODUCTION: MicroRNAs (miRNAs) are regulators of gene expression, which play an important role in many critical cellular processes including apoptosis, proliferation and cell differentiation. Aberrant miRNA expression has been reported in a variety of human malignancies. Therefore, miRNAs may be potentially used as cancer biomarkers. miRNA-200c, which is a member of the miRNA-200 family, might play an essential role in tumor progression. The purpose of this study was to evaluate the prognostic and clinical significance of miRNA-200c in women with endometrioid endometrial cancer. MATERIAL AND METHODS: Total RNA extraction from 90 archival formalin-fixed paraffin-embedded tissue samples of endometri-oid endometrial cancer and 10 normal endometrium samples was performed. After cDNA synthesis, real-time polymerase chain reaction was conducted and relative expression of miRNA-200c was assessed. Then, miRNA-200c expression levels were evaluated with regard to clinicopathological characteristics. RESULTS: The expression levels of miRNA-200c were significantly increased in endometrioid endometrial cancer samples. Expression of miRNA-200c maintained at significantly higher levels in the early stage endometrioid endometrial cancer compared with more advanced stages. In the Kaplan-Meier analysis, lower levels of miRNA-200c expression were associated with inferior survival. CONCLUSIONS: Expression levels of miRNA-200c might be associated with clinicopathological factors and survival in endometrioid endometrial cancer.
INTRODUCTION: MicroRNAs (miRNAs) are regulators of gene expression, which play an important role in many critical cellular processes including apoptosis, proliferation and cell differentiation. Aberrant miRNA expression has been reported in a variety of humanmalignancies. Therefore, miRNAs may be potentially used as cancer biomarkers. miRNA-200c, which is a member of the miRNA-200 family, might play an essential role in tumor progression. The purpose of this study was to evaluate the prognostic and clinical significance of miRNA-200c in women with endometrioid endometrial cancer. MATERIAL AND METHODS: Total RNA extraction from 90 archival formalin-fixed paraffin-embedded tissue samples of endometri-oid endometrial cancer and 10 normal endometrium samples was performed. After cDNA synthesis, real-time polymerase chain reaction was conducted and relative expression of miRNA-200c was assessed. Then, miRNA-200c expression levels were evaluated with regard to clinicopathological characteristics. RESULTS: The expression levels of miRNA-200c were significantly increased in endometrioid endometrial cancer samples. Expression of miRNA-200c maintained at significantly higher levels in the early stage endometrioid endometrial cancer compared with more advanced stages. In the Kaplan-Meier analysis, lower levels of miRNA-200c expression were associated with inferior survival. CONCLUSIONS: Expression levels of miRNA-200c might be associated with clinicopathological factors and survival in endometrioid endometrial cancer.
Authors: Gloria Ravegnini; Francesca Gorini; Eugenia De Crescenzo; Antonio De Leo; Dario De Biase; Marco Di Stanislao; Patrizia Hrelia; Sabrina Angelini; Pierandrea De Iaco; Anna Myriam Perrone Journal: Int J Cancer Date: 2021-11-17 Impact factor: 7.316
Authors: Ping Liu; Chengbin Ma; Qiongwei Wu; Wenying Zhang; Cao Wang; Li Yuan; Xiaowei Xi Journal: Cancer Cell Int Date: 2019-07-11 Impact factor: 5.722